KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Current Assets (2016 - 2025)

AbbVie (ABBV) has disclosed Current Assets for 14 consecutive years, with $29.1 billion as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets rose 13.6% to $29.1 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $29.1 billion, a 13.6% increase, with the full-year FY2025 number at $29.1 billion, up 13.6% from a year prior.
  • Current Assets was $29.1 billion for Q4 2025 at AbbVie, up from $28.5 billion in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $38.9 billion in Q1 2024 to a low of $25.6 billion in Q4 2024.
  • A 5-year average of $29.3 billion and a median of $28.7 billion in 2023 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: tumbled 48.67% in 2021, then skyrocketed 46.75% in 2024.
  • AbbVie's Current Assets stood at $27.9 billion in 2021, then rose by 1.92% to $28.5 billion in 2022, then increased by 15.95% to $33.0 billion in 2023, then decreased by 22.48% to $25.6 billion in 2024, then rose by 13.6% to $29.1 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Current Assets are $29.1 billion (Q4 2025), $28.5 billion (Q3 2025), and $29.3 billion (Q2 2025).